Drug intelligence / Profile preview

phenylephrine + nitric oxide

Development stage: Preclinical
Lead developer: Johnson & Johnson Consumer Inc. (J&JCI)
Modality: Small Molecules
Administration: Intravenous, Inhalation

Overview

A combination therapy consisting of phenylephrine, an alpha-1 adrenergic receptor agonist that causes vasoconstriction, and nitric oxide, a selective vasodilator. This combination has been studied for its complementary effects in improving oxygenation in patients with adult respiratory distress syndrome (ARDS). In phenylephrine-responsive patients, the combination produces greater improvement in oxygenation than either treatment alone, likely through selective enhancement of hypoxic pulmonary vasoconstriction by phenylephrine complementing the selective vasodilation by nitric oxide.

Targets

sGC (Soluble Guanylyl Cyclase)ADRA1A (α1A)

Beyond the preview

Go deeper on phenylephrine + nitric oxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phenylephrine + nitric oxide.

Explore the full profile